The DNMT3A Knockout NCI-H1703 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1703 human lung squamous cell carcinoma line. This product is designed for loss-of-function studies by disrupting the DNMT3A gene, which encodes a critical de novo DNA methyltransferase. The polyclonal format provides a genetically heterogeneous population that reflects the average effect of target-gene disruption across multiple editing events, enabling robust phenotypic analysis without clonal selection bias. These cells are an ideal tool for investigating the epigenetic mechanisms underlying lung cancer and for screening DNA methylation-targeted therapeutics.
The parental NCI-H1703 cell line is a well-characterized model of non-small cell lung cancer (NSCLC), specifically squamous cell carcinoma. Originating from a primary lung squamous cell carcinoma, these cells harbor a TP53 mutation and grow as an adherent epithelial monolayer. NCI-H1703 is widely used to study NSCLC biology, drug responses, and the role of epigenetic alterations in tumor progression. Its genetic background makes it particularly suitable for examining the interplay between epigenetic silencing and genomic instability in lung carcinogenesis.
DNMT3A functions as a de novo DNA methyltransferase that establishes DNA methylation patterns during development and disease. It catalyzes the transfer of methyl groups from S-adenosylmethionine to CpG dinucleotides, leading to transcriptional repression of target genes. DNMT3A is activated by upstream regulators such as SPI1, GATA1, and RUNX1, and its activity is modulated through interactions with DNMT3L, DNMT3B, and chromatin modifiers including HDAC1, HDAC2, and EZH2. This enzyme cooperates with UHRF1 and PCNA to target nascent DNA for methylation. Its downstream targets include key tumor suppressor genes like CDKN2A (p16), RASSF1, FHIT, APC, MGMT, and CDH1 (E-cadherin), which are frequently silenced by hypermethylation in cancer. Disruption of DNMT3A disrupts this epigenetic silencing machinery, potentially restoring expression of these critical growth-regulatory genes.
In the context of NCI-H1703 lung cancer cells, DNMT3A knockout is predicted to reduce aberrant CpG island hypermethylation, thereby reactivating silenced tumor suppressors and altering oncogenic pathways. Given that DNMT3A overexpression and hyperactivity contribute to epigenetic silencing in squamous cell carcinoma, its loss provides a model to study the reversal of these marks. This knockout cell population is valuable for dissecting the contribution of de novo methylation to lung cancer phenotypes, including proliferation, apoptosis, and invasion. It also serves as a platform to examine how the IL-6/STAT3 signaling axis regulates DNMT3A expression and the downstream effects on Wnt/??-catenin pathway components.
These polyclonal knockout cells are suited for a diverse array of research applications, including epigenetic drug screening using decitabine sensitivity assays, DNA methylation profiling via bisulfite sequencing and methylation-specific PCR, and tumor suppressor gene reactivation studies employing RT-qPCR and Western blotting. They enable functional genomics experiments through RNA-seq and ChIP-qPCR for histone modifications, as well as phenotypic analyses such as MTT viability assays, Annexin V apoptosis assays, and transwell invasion assays. Researchers can exploit this model to validate CRISPR-based gene editing outcomes and to explore crosstalk between DNA methylation and other epigenetic marks in lung cancer. For further information, please contact Ascent Research.
